{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028201","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.761719+00:00","generated_at":"2026-06-12T03:21:24.274698+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioLife Q2 revenue falls 3% to $39.5M; net loss $0.23/share; cuts FY guidance; plans freezer divest","bullets":["Q2 2023 revenue $39.5M, down 3% YoY; cell processing up 22% but freezers down 26%.","GAAP net loss $10.2M ($0.23 EPS); adjusted EBITDA -$1.2M vs +$1.2M a year ago.","FY2023 revenue guidance lowered to $144M-$158M; previous cell processing guidance $89-93M now $65-74M.","Committed to divest Stirling Ultracold and CBS freezer assets by end of 2023; focus on recurring higher-margin products.","Pro forma H1 2023 revenue ex-freezers $51.5M; adj. gross margin 52%; adj. EBITDA margin 16-18%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028201","json":"https://secwatch.observer/filing/0001628280-23-028201.json","markdown":"https://secwatch.observer/filing/0001628280-23-028201.md","text":"https://secwatch.observer/filing/0001628280-23-028201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828023028201/0001628280-23-028201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828023028201/blfs-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:21:24.274698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"907715774bc59b096e4a2801e2a3d92543bcd929","claim":"BIOLIFE SOLUTIONS INC updated its second quarter ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On August 8, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828023028201/0001628280-23-028201-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}